Cell therapy weekly: Novo Nordisk continues to investigate stem cell therapies for chronic diseases and Kite expands manufacturing capability
This week: FDA accepts IND for gene-edited sickle cell therapy and severe hemophilia A patients targeted in phase I/II study.
Please sign in or register for FREE
Sign in to RegMedNet
Register to RegMedNet
RegMedNet is a free content and networking hub promoting global connection, knowledge-sharing and collaboration between all members of the regenerative medicine field.